Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efgartigimod alfa - argenx

Drug Profile

Efgartigimod alfa - argenx

Alternative Names: ARGX-113; EFG PH20 SC; Efgartigimod - argenx; Efgartigimod alfa-fcab - argenx; efgartigimod PH20; efgartigimod PH20 SC; PH20 SC; VYVDURA; VYVGART; VYVGART HYTRULO

Latest Information Update: 19 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator arGEN-X
  • Developer argenx; Medison; ZAI Lab
  • Class Anti-inflammatories; Antiarrhythmics; Immunoglobulin Fc fragments; Monoclonal antibodies; Skin disorder therapies; Urologics
  • Mechanism of Action Neonatal Fc receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura; Chronic inflammatory demyelinating polyradiculoneuropathy; Myasthenia gravis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Myasthenia gravis
  • Registered Idiopathic thrombocytopenic purpura
  • Preregistration Chronic inflammatory demyelinating polyradiculoneuropathy
  • Phase III Bullous pemphigoid; Graves ophthalmopathy; Myositis; Pemphigus
  • Phase II Lupus nephritis; Membranous glomerulonephritis; Sjogren's syndrome
  • Clinical Phase Unknown Renal transplant rejection
  • Preclinical Immune-mediated necrotising myopathy
  • Discontinued Anti-neutrophil cytoplasmic antibody-associated vasculitis; Postural orthostatic tachycardia syndrome

Most Recent Events

  • 17 Jun 2024 Discontinued - Phase-II for Postural orthostatic tachycardia syndrome in USA (IV)
  • 17 Jun 2024 Efficacy and adverse events data from a phase II ALPHA trial in Postural orthostatic tachycardia syndrome released by argenx
  • 16 May 2024 Discontinued - Clinical-Phase-Unknown for Anti-neutrophil cytoplasmic antibody-associated vasculitis (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top